U.S. markets close in 4 hours 21 minutes
  • S&P 500

    3,641.36
    -77.68 (-2.09%)
     
  • Dow 30

    29,233.16
    -450.58 (-1.52%)
     
  • Nasdaq

    10,731.99
    -319.65 (-2.89%)
     
  • Russell 2000

    1,665.95
    -49.30 (-2.87%)
     
  • Crude Oil

    82.15
    0.00 (0.00%)
     
  • Gold

    1,665.40
    -4.60 (-0.28%)
     
  • Silver

    18.71
    -0.17 (-0.90%)
     
  • EUR/USD

    0.9786
    +0.0047 (+0.48%)
     
  • 10-Yr Bond

    3.7570
    +0.0520 (+1.40%)
     
  • GBP/USD

    1.1049
    +0.0163 (+1.50%)
     
  • USD/JPY

    144.4560
    +0.3340 (+0.23%)
     
  • BTC-USD

    19,269.86
    -121.80 (-0.63%)
     
  • CMC Crypto 200

    440.99
    -4.99 (-1.12%)
     
  • FTSE 100

    6,867.57
    -137.82 (-1.97%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

Merck Bets $250M On Next-Gen Approach To mRNA For Infectious Diseases, Cancer

·1 min read
  • Merck Co & Inc (NYSE: MRK) and Orna Therapeutics announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in infectious disease and oncology.

  • Merck will make an upfront payment to Orna of $150 million. In addition, Orna will be eligible to receive up to $3.5 billion in development, regulatory, and sales milestones.

  • Orna will retain rights to its engineered circular RNA (oRNA) therapies (oRNA)-lipid nanoparticles (LNP) technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease.

  • Merck will also invest $100 million of equity in Orna's recently completed Series B financing round.

  • oRNA molecules have been shown to have greater stability in vivo than linear mRNA and have the potential to produce larger quantities of therapeutic proteins inside the body.

  • Newly synthesized oRNA molecules are more compactly packaged into custom LNPs, which Orna has engineered to target key tissues in the body.

  • Preclinical data has demonstrated the potential of oRNA expression and delivery as an approach for further development in vaccines and oncology therapeutics.

  • Price Action: MRK shares are up 0.08% at $90.87 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.